Abstract
The discovery of hepatocyte growth factor (HGF) in the early 1980s was followed by years of research into its role as an essential factor for normal human growth and development as well as its putative role in neoplasia signaling. The recognition that HGF and its tyrosine kinase receptor, mesenchymal-epithelial transition (MET) factor, constitute an essential signaling pathway in many cancers led to the development of corresponding targeted therapies. The signaling mediated by the HGF/c-Met system mediates crucial downstream effects in gliomas and is therefore considered a highly important target in these tumors. This review examines the research into the HGF/c-Met pathway in cancer with a focus on gliomas.
| Original language | English |
|---|---|
| Title of host publication | Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy |
| Subtitle of host publication | Second Edition |
| Publisher | Elsevier Inc. |
| Pages | 341-346 |
| Number of pages | 6 |
| ISBN (Print) | 9780128121009 |
| DOIs | |
| State | Published - Apr 24 2018 |
Keywords
- Glioblastoma
- Hepatocyte growth factor
- Mesenchymal-epithelial transition factor
- Receptor tyrosine kinase
Fingerprint
Dive into the research topics of 'Scatter Factor/HGF and c-Met in Glioblastoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver